Tatiana Novobrantseva

This inventor holds 30 USPTO granted patents and 23 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Lipid Formulations. Top assignees: Alnylam Pharmaceuticals, Inc., US Government as Represented by the Secretary of the Army, Biogen Idec Ma Inc.. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatiana Novobrantseva. Retrieved from https://idiyas.com/inventor/tatiana-novobrantseva

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 23)

% Patents Active = 73.3

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 24)

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 53(Granted Patents)

Location History:

Quincy, MA (US) (2012)
Cambridge, MA (US) (2011 - 2020)
Wellesley, MA (US) (2010 - 2024)

Company Filing History:

26 out of 466

Alnylam Pharmaceuticals, Inc.

patents

5 out of 8,748

US Government as Represented by the Secretary of the Army

Jounce Therapeutics, Inc.

patents

6. 1 out of 46

Voyager Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

Areas of Expertise:

Lipid Formulations

Gene Expression

Serum Amyloid A

CD274/PD-L1

Liver Fibrosis

Ebola Virus

B7-H4 Antibodies

Factor VII

BAFF Antagonists

Influenza Gene Expression

Lung Fibrosis

KLF-1

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11884919 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene (2024-01-30),

2. 11149273 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene (2021-10-19),

3. 10983110 - Assays for the detection of AAV neutralizing antibodies (2021-04-20),

4. 10745704 - Compositions and methods for inhibiting expression of CD274/PD-L1 gene (2020-08-18),

5. 10669303 - Compositions and methods directed to treating liver fibrosis (2020-06-02),

6. 10626176 - Methods of treating conditions with antibodies that bind B7-H4 (2020-04-21),

7. 10472628 - Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene (2019-11-12),

8. 9944671 - Compositions and methods directed to treating liver fibrosis (2018-04-17),

9. 9932593 - Compositions and methods for inhibiting expression of CD274/PD-L1 gene (2018-04-03),

10. 9868950 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene (2018-01-16),

11. 9422562 - Compositions and methods for inhibiting expression of CD274/PD-L1 gene (2016-08-23),

12. 9206421 - Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene (2015-12-08),

13. 9187516 - Compositions and methods for inhibiting expression of a gene from the Ebola virus (2015-11-17),

14. 9127275 - Compositions and methods for inhibiting expression of klf-1 and bcl11a genes (2015-09-08),

15. 9062310 - Compositions and methods for inhibiting expression of factor VII gene (2015-06-23),

Title: Inventor Tatiana Novobrantseva - Revolutionizing Biomedical Technologies

Introduction: Tatiana Novobrantseva is a pioneering inventor based in Wellesley, MA, known for her groundbreaking work in the field of biomedical technologies.

Latest Patents: Tatiana Novobrantseva holds several patents related to innovative drug delivery systems and medical devices designed to improve patient outcomes and revolutionize the healthcare industry.

Career Highlights: With a background in bioengineering and a passion for improving healthcare, Tatiana Novobrantseva has successfully translated her research into practical solutions that have the potential to impact millions of lives worldwide.

Collaborations: Throughout her career, Tatiana Novobrantseva has collaborated with leading researchers, medical professionals, and industry experts to bring her inventions from concept to reality, fostering a culture of innovation and excellence in the biomedical field.

Conclusion: Tatiana Novobrantseva's dedication to pushing the boundaries of biomedical technologies and her commitment to improving patient care make her a true visionary in the world of inventions and innovations.

Profile summary based on public USPTO records.